In mouse models of experimental colitis, DPP-4 inhibition increases GLP-2 levels, attenuates inflammation, reduces disease severity, and supports mucosal healing through the suppression of T cell proliferation and cytokine production [75,99,100,101,102]. The gene discussed is GCG; the disease is colitis.